Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending June 21, 2012. The report details a specific share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,200,000 Ordinary shares of 25 pence each.
- Purchase Date: June 21, 2012.
- Price Range: Highest price paid was 1,479.5 pence per share; lowest price paid was 1,462.5 pence per share.
- Treasury Holdings (Settled): 468,507,927 shares (8.57% of total issued share capital).
- Treasury Holdings (Including Unsettled): 472,107,927 shares (9.45% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,997,902,500 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 1,200,000 shares for Treasury. This transaction increased the percentage of total voting rights held in Treasury from the prior settled position to 9.45% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Points
- Verify the total number of shares in issue (4,997,902,500) to calculate individual ownership percentages under Disclosure and Transparency Rules.
- Confirm the settlement status of the 3,600,000 shares difference between settled and unsettled Treasury holdings.
- Review the remaining authorization for share buybacks following this transaction.